Funding for this grant has been made possible by unrestricted educational grants to the American Psychiatric Foundation from Forest Laboratories, Inc., and Wyeth Pharmaceuticals. The authors acknowledge the significant contributions of the 17 psychiatric practices that participated in the original NDMLI and the subsequent follow-up. The authors also thank the consultants for their contributions to the study and staff for assisting with the project implementation.
Dr. Chung has served as a consultant to Takeda Pharmaceuticals and Lundbeck. Dr. Katzelnick is a principal shareholder of stock in Healthcare Technology Systems. Dr. Trivedi is or has been an advisor or consultant to Alkermes; AstraZeneca; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly & Company; Evotec; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Lundbeck; MedAvante; Neuronetics; Otsuka Pharmaceuticals; Pamlab; Pfizer, Inc.; Rexahn Pharmaceuticals; Sepracor; SHIRE Development; Takeda; and Tal Medical/Puretech Venture. He has received research support from Valient. The other authors report no competing interests.